It depends on the standard you follow. As of September 2026, AbbVie Inc. (ABBV) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 16.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 2.31% / 30% · Interest income / Revenue 0.59% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 16.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 2.23% / 33% · Receivables / Mkt Cap (36m) 2.80% / 49% · Interest income / Revenue 0.59% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 16.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 2.23% / 33.33% · Receivables / Mkt Cap (24m) 2.80% / 33.33% · Interest income / Revenue 0.59% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 52.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 5.78% / 33.33% · Receivables / Avg Assets (4Q) 9.47% / 33.33% · Interest income / Revenue 0.59% / 5% | Fail |
| FTSE | Debt / Total Assets 54.8% / 33.33% · (Cash+ST Inv) / Total Assets 7.30% / 33.33% · (Cash+Recv) / Total Assets 16.4% / 33.33% · Interest income / Revenue 0.59% / 5% | Fail |
It depends on the standard you follow. As of September 2026, AbbVie Inc. (ABBV) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. AbbVie Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.59% of each dividend: AbbVie Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
AbbVie Inc. (NYSE: ABBV) is a Healthcare company (Drug Manufacturers - General) with a market capitalization of $520.9B. The Maz Rating grades it against the other companies in its sector.
AbbVie Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $294.67, AbbVie Inc. trades at 50.5x trailing earnings and 7.9x sales, with an EV/EBITDA of 23.5. Over the last twelve months it generated about $66.0B of revenue and $10.3B of net income. It runs a gross margin of 73.7%, an operating margin of 32.2% and a net margin of 15.7%. It shows return on equity of -202.3%, return on invested capital of 15.1% and a free cash flow yield of 3.6%. On the balance sheet: a debt-to-equity ratio of -17.65 and a current ratio of 0.87. Over the past 52 weeks the share price ranged from $190.75 to $302.93, with a beta of 0.28.
AbbVie Inc. pays a dividend yielding 2.35%, with 117% of earnings paid out. Its Maz Dividend Score is 2.43 out of 5, ranked against the other dividend payers in its sector (Safety 1.57, Growth 4.10, Yield 4.23, Consistency 2.53).
44 Wall Street analyst ratings cover the stock: 31 Buy, 12 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.